Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7E11-13G9
- Development stage
- Unknown
- Lead developer
- Shanghai Genbase Biotechnology
- Modality
- Antibody-Based Therapeutics
01
Overview
7E11-13G9: sourced facts only. name: "By the strong CD19 binding arm of 7E11 and the efficient CD22-mediated internalizing arm of 13G9, 7E11-13G9 BsAb kills more tumor cells with high potency and efficacy." [DOI:10.1158/1538-7445.am2022-5553]; target: "By the strong CD19 binding arm of 7E11 and the efficient CD22-mediated internalizing arm of 13G9, 7E11-13G9 BsAb kills more tumor cells with high potency and efficacy." [DOI:10.1158/1538-7445.am2022-5553]; developer: "1Shanghai Genbase Biotechnology Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2022-5553]; modality: "we developed 7E11-13G9, which is a bispecific antibody designed for antibody-drug-conjugate for a larger market of B-cell hematological cancers." [DOI:10.1158/1538-7445.am2022-5553]
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on 7E11-13G9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7E11-13G9.